{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:47:08Z","timestamp":1771480028453,"version":"3.50.1"},"reference-count":98,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T00:00:00Z","timestamp":1528761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title\/><jats:p>The natural history of mantle cell lymphoma (MCL) undergoing chemotherapy is a cyclical pattern of remission followed by recurrence of disease due to acquired chemotherapy resistance. The median age of the occurrence of MCL is 65 years, so half of the newly diagnosed MCL patients are considered \u201celderly.\u201d The tolerance to long-term chemotherapy in elderly patients is decreased; hence, the response to frontline therapy used is of paramount importance. We hope that our review may guide clinicians in treating such populations in a more personalized and evidence-based manner.<\/jats:p><jats:p>In the older patients with risk variables, frontline treatment is determined according to different body status of fit, unfit or compromised, and frail. In the fit patients, the pursuit of remission and prolongation of survival might currently justify the use of more intense and toxic therapies. For unfit or compromised older patients, disease control needs to be prioritized, maintaining a balance between the benefits and toxicities of the treatment. For frail patients, tolerance of treatment and minimizing myelotoxicity should be the primary focus. \u201cChemotherapy-free\u201d regimens are likely to be considered as the first-line strategy for this population. On the other hand, in the older MCL population without risk variables, observation or \u201cwatch and wait\u201d can prevent overtreatment. Furthermore, more clinical trials and research studies on novel agents and targeted therapies need to be translated into the general population to provide optimal treatment and to guide personalized treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Implications for Practice<\/jats:title><jats:p>This review emphasizes the importance of frontline therapies for older MCL patients. MCL patients commonly experience a cyclical pattern of remission followed by recurrence of disease due to acquired chemotherapy resistance. As a special population, elderly patients have various comorbidities and decreased organ function, which may reduce the chances of undergoing treatment for recurrent disease. Thus, this older population of patients with MCL should be treated separately and exceptionally. So far, systematic reviews with regard to frontline treatment for older patients with MCL have not been encountered, but the hope is that this review may guide clinicians in treating such populations in a more personalized and evidence-based manner.<\/jats:p><\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0470","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T17:10:20Z","timestamp":1528823420000},"page":"1337-1348","source":"Crossref","is-referenced-by-count":11,"title":["Frontline Treatment for Older Patients with Mantle Cell Lymphoma"],"prefix":"10.1093","volume":"23","author":[{"given":"Haige","family":"Ye","sequence":"first","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China"},{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aakash","family":"Desai","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"The University of Texas Health Science Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongfeng","family":"Zeng","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Romaguera","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Wang","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,6,12]]},"reference":[{"key":"2021122511252168000_onco12571-bib-0001","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/asheducation-2009.1.542","article-title":"European MCL Network. Current treatment standards and emerging strategies in mantle cell lymphoma","author":"Dreyling","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2021122511252168000_onco12571-bib-0002","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122511252168000_onco12571-bib-0003","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.2002.20.2.494","article-title":"Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: An Italian Group for Geriatric Oncology study","volume":"20","author":"Repetto","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122511252168000_onco12571-bib-0004","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1002\/cncr.24490","article-title":"A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy","volume":"115","author":"Tucci","year":"2009","journal-title":"Cancer"},{"key":"2021122511252168000_onco12571-bib-0005","first-page":"30","article-title":"New paradigms for treating elderly patients with cancer: The comprehensive geriatric assessment and guidelines for supportive care","volume":"1","author":"Balducci","year":"2003","journal-title":"J Support Oncol"},{"key":"2021122511252168000_onco12571-bib-0006","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3324\/haematol.2014.119115","article-title":"European Mantle Cell Lymphoma Network. The role of targeted treatment in mantle cell lymphoma: Is transplant dead or alive?","volume":"101","author":"Dreyling","year":"2016","journal-title":"Haematologica"},{"key":"2021122511252168000_onco12571-bib-0007","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2011.162","article-title":"Impact of TP53 mutation and 17p deletion in mantle cell lymphoma","volume":"25","author":"Halldorsdottir","year":"2011","journal-title":"Leukemia"},{"key":"2021122511252168000_onco12571-bib-0008","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3324\/haematol.2011.055715","article-title":"The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: P53 alterations and blastoid morphology are strong predictors of a high proliferation index","volume":"97","author":"Slotta-Huspenina","year":"2012","journal-title":"Haematologica"},{"key":"2021122511252168000_onco12571-bib-0009","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302","article-title":"P53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis","volume":"87","author":"Greiner","year":"1996","journal-title":"Blood"},{"key":"2021122511252168000_onco12571-bib-0010","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/blood.V87.8.3351.bloodjournal8783351","article-title":"P53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas","volume":"87","author":"Hernandez","year":"1996","journal-title":"Blood"},{"key":"2021122511252168000_onco12571-bib-0011","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood"},{"key":"2021122511252168000_onco12571-bib-0012","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Bea","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122511252168000_onco12571-bib-0013","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cell.2012.08.026","article-title":"Transcriptional amplification in tumor cells with elevated c-MYC","volume":"151","author":"Lin","year":"2012","journal-title":"Cell"},{"key":"2021122511252168000_onco12571-bib-0014","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2141.2010.08159.x","article-title":"Advances in the understanding of MYC-induced lymphomagenesis","volume":"149","author":"Klapproth","year":"2010","journal-title":"Br J Haematol"},{"key":"2021122511252168000_onco12571-bib-0015","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10428190009053541","article-title":"Untreated aggressive mantle cell lymphoma: Results with intensive chemotherapy without stem cell transplant in elderly patients","volume":"39","author":"Romaguera","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"2021122511252168000_onco12571-bib-0016","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122511252168000_onco12571-bib-0017","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"key":"2021122511252168000_onco12571-bib-0018","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/annonc\/mdt070","article-title":"A phase II multicenter trial of hyperCVAD MTX\/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213","volume":"24","author":"Bernstein","year":"2013","journal-title":"Ann Oncol"},{"key":"2021122511252168000_onco12571-bib-0019","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjh.13796","article-title":"Rituximab plus hyper-CVAD alternating with MTX\/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center","volume":"172","author":"Chihara","year":"2016","journal-title":"Br J Haematol"},{"key":"2021122511252168000_onco12571-bib-0020","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.2011.08958.x","article-title":"Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi","volume":"156","author":"Merli","year":"2012","journal-title":"Br J Haematol"},{"key":"2021122511252168000_onco12571-bib-0021","doi-asserted-by":"crossref","first-page":"151a","DOI":"10.1182\/blood.V120.21.151.151","article-title":"Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: Final analysis of the MCL younger trial of the European Mantle Cell Lymphoma Network (MCL net)","volume":"120","author":"Hermine","year":"2012","journal-title":"Blood"},{"key":"2021122511252168000_onco12571-bib-0022","doi-asserted-by":"crossref","first-page":"146a","DOI":"10.1182\/blood.V124.21.146.146","article-title":"Rituximab maintenance versus wait and watch after four courses of R-DHAP followed by autologous stem cell transplantation in previously untreated young patients with mantle cell lymphoma: First interim analysis of the phase III prospective Lyma trial, a Lysa study","volume":"124","author":"Gouill","year":"2014","journal-title":"Blood"},{"key":"2021122511252168000_onco12571-bib-0023","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: A phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"key":"2021122511252168000_onco12571-bib-0024","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2141.2008.07498.x","article-title":"High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients","volume":"144","author":"'t Veer","year":"2009","journal-title":"Br J Haematol"},{"key":"2021122511252168000_onco12571-bib-0025","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.3109\/10428194.2012.672736","article-title":"Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: A prospective study by the Finnish Lymphoma Group","volume":"53","author":"Raty","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"2021122511252168000_onco12571-bib-0026","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3109\/10428190903518345","article-title":"High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma","volume":"51","author":"Lossos","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"2021122511252168000_onco12571-bib-0027","first-page":"1580","article-title":"High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma","volume":"90","author":"Vigouroux","year":"2005","journal-title":"Haematologica"},{"key":"2021122511252168000_onco12571-bib-0028","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3324\/haematol.10608","article-title":"Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: Effects on molecular response and clinical outcome","volume":"92","author":"Dreger","year":"2007","journal-title":"Haematologica"},{"key":"2021122511252168000_onco12571-bib-0029","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"2021122511252168000_onco12571-bib-0030","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2014.223","article-title":"The EBMT\/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma","volume":"29","author":"Robinson","year":"2015","journal-title":"Leukemia"},{"key":"2021122511252168000_onco12571-bib-0031","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/sj.bmt.1705371","article-title":"Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma","volume":"37","author":"Buadi","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"2021122511252168000_onco12571-bib-0032","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1200\/JCO.2006.09.1215","article-title":"High-dose [131i]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults\u2009&gt;\u2009or\u2009=\u200960 years old with relapsed or refractory B-cell lymphoma","volume":"25","author":"Gopal","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122511252168000_onco12571-bib-0033","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/sj.bmt.1702833","article-title":"Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-hodgkin's lymphoma in adults 60 years of age and older","volume":"27","author":"Gopal","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"2021122511252168000_onco12571-bib-0034","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.clml.2014.07.017","article-title":"R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma","volume":"15","author":"Frosch","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2021122511252168000_onco12571-bib-0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.bmt.1702736","article-title":"Transplant-related mortality in patients older than 60 years undergoing autologous hematopoietic stem cell transplantation","volume":"27","author":"la Rubia","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"2021122511252168000_onco12571-bib-0036","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/annonc\/mdr035","article-title":"Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: A study from the European Group for Blood and Marrow Transplantation (EBMT)","volume":"23","author":"Jantunen","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122511252168000_onco12571-bib-0037","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"2021122511252168000_onco12571-bib-0038","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S2352-3026(16)30187-9","article-title":"Bendamustine-rituximab in mantle cell lymphoma","volume":"4","author":"Lipsky","year":"2017","journal-title":"Lancet Haematol"},{"key":"2021122511252168000_onco12571-bib-0039","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-hodgkin lymphoma ineligible for intensive regimens or autologous transplantation","volume":"31","author":"Visco","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122511252168000_onco12571-bib-0040","first-page":"100","article-title":"Rituximab, bendamustine and cytarabine (RBAC500) as induction therapy in elderly patients with mantle cell lymphoma: A phase 2 study from the Fondazione Italiana Linfomi","volume":"33","year":"2015","journal-title":"Hematol Oncol"},{"key":"2021122511252168000_onco12571-bib-0041","first-page":"100","article-title":"Rituximab, bendamustine and cytarabine (rbac500) as induction therapy in elderly patients with mantle cell lymphoma: A phase 2 study from the fondazione italiana linfomi","volume":"33","author":"Visco","year":"2015","journal-title":"Hematological oncology"},{"key":"2021122511252168000_onco12571-bib-0042","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","article-title":"Bendamustine: Rebirth of an old drug","volume":"27","author":"Cheson","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122511252168000_onco12571-bib-0043","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122511252168000_onco12571-bib-0044","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122511252168000_onco12571-bib-0045","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","article-title":"Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: Results from a multicenter study","volume":"116","author":"Kahl","year":"2010","journal-title":"Cancer"},{"key":"2021122511252168000_onco12571-bib-0046","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","article-title":"Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: A multicentre, randomised, open-label, non-inferiority phase 3 trial","volume":"17","author":"Rummel","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122511252168000_onco12571-bib-0047","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s12185-015-1767-3","article-title":"A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study","volume":"101","author":"Matsumoto","year":"2015","journal-title":"Int J Hematol"},{"key":"2021122511252168000_onco12571-bib-0048","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"suppl 15","key":"2021122511252168000_onco12571-bib-0049","first-page":"7500a","article-title":"First-line treatment of iNHL or MCL patients with BR or R-CHOP\/R-CVP: Results of the BRIGHT 5-year follow-up study. J Clin","volume":"35","author":"Flinn","year":"2017","journal-title":"Oncol"},{"key":"2021122511252168000_onco12571-bib-0050","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00432-005-0023-2","article-title":"Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: Results of a randomised phase III trial (OSHO# 19)","volume":"132","author":"Herold","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"2021122511252168000_onco12571-bib-0051","doi-asserted-by":"crossref","first-page":"370a","DOI":"10.1182\/blood.V122.21.370.370","article-title":"The RIBVD regimen (rituximab IV, bendamustine IV, velcade SC, dexamethasone IV) offers a high complete response rate in elderly patients with untreated mantle cell lymphoma. Preliminary results of the Lysa trial \u201cLymphome Du Manteau 2010 SA","volume":"122","author":"Gressin","year":"2013","journal-title":"Blood"},{"key":"2021122511252168000_onco12571-bib-0052","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood.V124.21.148.148","article-title":"Frontline therapy with the RIBVD regimen elicits high clinical and molecular response rates and long PFS in elderly patients mantle cell lymphoma (MCL); final results of a prospective phase II trial by the Lysa group","volume":"124","author":"Gressin","year":"2014","journal-title":"Blood"},{"key":"2021122511252168000_onco12571-bib-0053","doi-asserted-by":"crossref","first-page":"523842","DOI":"10.1155\/2012\/523842","article-title":"Therapeutic activity of lenalidomide in mantle cell lymphoma and indolent non-Hodgkin's lymphomas","volume":"2012","author":"Gunnellini","year":"2012","journal-title":"Adv Hematol"},{"key":"2021122511252168000_onco12571-bib-0054","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122511252168000_onco12571-bib-0055","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1182\/blood-2016-03-704023","article-title":"Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma\u2009&gt;\u200965 years, the Nordic Lymphoma Group phase I+II trial NLG-MCl4","volume":"128","author":"Albertsson-Lindblad","year":"2016","journal-title":"Blood"},{"key":"2021122511252168000_onco12571-bib-0056","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1365-2141.2011.08820.x","article-title":"VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: A Wisconsin Oncology Network Study","volume":"155","author":"Chang","year":"2011","journal-title":"Br J Haematol"},{"key":"2021122511252168000_onco12571-bib-0057","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","article-title":"Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis","volume":"171","author":"Pham","year":"2003","journal-title":"J Immunol"},{"key":"2021122511252168000_onco12571-bib-0058","doi-asserted-by":"crossref","first-page":"461487","DOI":"10.1155\/2013\/461487","article-title":"The synthetic compound norcantharidin induced apoptosis in mantle cell lymphoma in vivo and in vitro through the PI3K-Akt-NF-kappa B signaling pathway","volume":"2013","author":"Lv","year":"2013","journal-title":"Evid Based Complement Alternat Med"},{"key":"2021122511252168000_onco12571-bib-0059","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.leu.2404959","article-title":"Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo","volume":"22","author":"Wang","year":"2008","journal-title":"Leukemia"},{"key":"2021122511252168000_onco12571-bib-0060","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/annonc\/mdl127","article-title":"Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: A pilot study from the Wisconsin Oncology Network","volume":"17","author":"Kahl","year":"2006","journal-title":"Ann Oncol"},{"key":"2021122511252168000_onco12571-bib-0061","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909","volume":"27","author":"Damon","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122511252168000_onco12571-bib-0062","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2013-08-523845","article-title":"Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group study (e1405)","volume":"123","author":"Chang","year":"2014","journal-title":"Blood"},{"key":"2021122511252168000_onco12571-bib-0063","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122511252168000_onco12571-bib-0064"},{"key":"2021122511252168000_onco12571-bib-0065","doi-asserted-by":"crossref","first-page":"A453","DOI":"10.1016\/j.jval.2015.09.1147","article-title":"Cost effectiveness of bortezomib, rituximab, cyclophosphamide, doxorubicin and prednisone for the first-line treatment of mantle cell lymphoma not eligible for stem cell transplantation: A Scottish perspective","volume":"18","author":"Keep","year":"2015","journal-title":"Value Health"},{"key":"2021122511252168000_onco12571-bib-0066","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/annonc\/mdr450","article-title":"Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RIPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: Results of a phase II trial from the GOELAMS","volume":"23","author":"Houot","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122511252168000_onco12571-bib-0067","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.1182\/blood.V126.23.5081.5081","article-title":"Rituximab maintenance therapy is an effective therapy in over-sixties with mantle cell lymphoma","volume":"126","author":"Inoue","year":"2015","journal-title":"Blood"},{"key":"2021122511252168000_onco12571-bib-0068","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2012.42.2444","article-title":"Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group study e1499","volume":"30","author":"Smith","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122511252168000_onco12571-bib-0069","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/leu.2016.305","article-title":"Mantle cell lymphoma initial therapy with abbreviated r-chop followed by (90)y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ecog-acrin study e1499","volume":"31","author":"Smith","year":"2017","journal-title":"Leukemia"},{"key":"2021122511252168000_onco12571-bib-0070","doi-asserted-by":"crossref","first-page":"37269","DOI":"10.1038\/srep37269","article-title":"Solid-liquid density and spin crossovers in (Mg, Fe)O system at deep mantle conditions","volume":"6","author":"Ghosh","year":"2016","journal-title":"Sci Rep"},{"key":"2021122511252168000_onco12571-bib-0071","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: A study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122511252168000_onco12571-bib-0072","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/1752-1947-7-173","article-title":"Primary uveal lymphoma effectively managed with oral chlorambucil: A case report","volume":"7","author":"Rospond-Kubiak","year":"2013","journal-title":"J Med Case Rep"},{"key":"2021122511252168000_onco12571-bib-0073","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.ophtha.2006.01.057","article-title":"Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit","volume":"113","author":"Ben Simon","year":"2006","journal-title":"Ophthalmology"},{"key":"2021122511252168000_onco12571-bib-0074","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/j.1939-1676.2011.0730.x","article-title":"Pharmacokinetics of cyclophosphamide after oral and intravenous administration to dogs with lymphoma","volume":"25","author":"Warry","year":"2011","journal-title":"J Vet Intern Med"},{"key":"2021122511252168000_onco12571-bib-0075","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1080\/10428190903093807","article-title":"Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: Final analysis of CALGB 8691","volume":"50","author":"Smith","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"2021122511252168000_onco12571-bib-0076","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1572-0241.2000.t01-1-01781.x","article-title":"Duodenal mucosa-associated lymphoid tissue lymphoma: Treatment with oral cyclophosphamide","volume":"95","author":"Lepicard","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"2021122511252168000_onco12571-bib-0077","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3109\/10428199809058396","article-title":"Mediastinal large-cell lymphoma with sclerosis refractory to conventional chemotherapy can respond after daily oral cyclophosphamide","volume":"29","author":"Benboubker","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"2021122511252168000_onco12571-bib-0078","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1002\/cncr.23422","article-title":"Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring\/refractory lymphoma: Low-dose metronomic, multidrug therapy","volume":"112","author":"Coleman","year":"2008","journal-title":"Cancer"},{"key":"2021122511252168000_onco12571-bib-0079","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2141.2010.08367.x","article-title":"Continuous oral cyclophosphamide and prednisolone as a valuable treatment option for peripheral T cell lymphoma","volume":"152","author":"Tucci","year":"2011","journal-title":"Br J Haematol"},{"key":"2021122511252168000_onco12571-bib-0080","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/10428199509064935","article-title":"A phase II trial of prednisone, oral etoposide, and novantrone (PEN) as initial treatment of non-Hodgkin's lymphoma in elderly patients","volume":"18","author":"Goss","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"2021122511252168000_onco12571-bib-0081","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2009-02-179739","article-title":"How I treat mantle cell lymphoma","volume":"114","author":"Ghielmini","year":"2009","journal-title":"Blood"},{"key":"2021122511252168000_onco12571-bib-0082","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2141.2005.05777.x","article-title":"Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma","volume":"131","author":"Bauwens","year":"2005","journal-title":"Br J Haematol"},{"key":"2021122511252168000_onco12571-bib-0083","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13045-015-0157-x","article-title":"Targeting neoplastic B cells and harnessing microenvironment: The \u201cdouble face\u201d of ibrutinib and idelalisib","volume":"8","author":"Maffei","year":"2015","journal-title":"J Hematol Oncol"},{"key":"2021122511252168000_onco12571-bib-0084","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-016-0250-9","article-title":"Acalabrutinib (ACP-196): A selective second-generation BTK inhibitor","volume":"9","author":"Wu","year":"2016","journal-title":"J Hematol Oncol"},{"key":"2021122511252168000_onco12571-bib-0085","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13045-016-0313-y","article-title":"Second-generation inhibitors of bruton tyrosine kinase","volume":"9","author":"Wu","year":"2016","journal-title":"J Hematol Oncol"},{"key":"2021122511252168000_onco12571-bib-0086","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/1060028016685803","article-title":"Venetoclax: A first-in-class oral BCL-2 inhibitor for the management of lymphoid malignancies","volume":"51","author":"King","year":"2017","journal-title":"Ann Pharmacother"},{"key":"2021122511252168000_onco12571-bib-0087","first-page":"1104","article-title":"Molecular target therapy for non-Hodgkin lymphoma [in Japanese]","volume":"72","author":"Kato","year":"2014","journal-title":"Nihon Rinsho"},{"key":"2021122511252168000_onco12571-bib-0088","doi-asserted-by":"crossref","first-page":"9837","DOI":"10.1158\/0008-5472.CAN-10-2650","article-title":"Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells","volume":"70","author":"Contag","year":"2010","journal-title":"Cancer Res"},{"key":"2021122511252168000_onco12571-bib-0089","first-page":"18","article-title":"Molecular target therapy for malignant lymphoma [in Japanese]","volume":"49","author":"Suzuki","year":"2008","journal-title":"Rinsho Ketsueki"},{"key":"2021122511252168000_onco12571-bib-0090","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1182\/blood-2006-05-020602","article-title":"Cd32b, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma","volume":"108","author":"Rankin","year":"2006","journal-title":"Blood"},{"key":"2021122511252168000_onco12571-bib-0091","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s10147-003-0295-y","article-title":"Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma","volume":"8","author":"Tobinai","year":"2003","journal-title":"Int J Clin Oncol"},{"key":"2021122511252168000_onco12571-bib-0092","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","article-title":"New development in CAR-T cell therapy","volume":"10","author":"Wang","year":"2017","journal-title":"J Hematol Oncol"},{"key":"2021122511252168000_onco12571-bib-0093","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122511252168000_onco12571-bib-0094","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.clml.2014.07.003","article-title":"Radiation therapy is an effective modality in the treatment of mantle cell lymphoma, even in heavily pretreated patients","volume":"14","author":"Haque","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2021122511252168000_onco12571-bib-0095","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle cell lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122511252168000_onco12571-bib-0096","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood.V128.22.147.147","article-title":"Chemotherapy-free induction with ibrutinib-rituximab followed by shortened cycles of chemo-immunotherapy consolidation in young, newly diagnosed mantle cell lymphoma patients: A phase II clinical trial","volume":"128","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"2021122511252168000_onco12571-bib-0097","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122511252168000_onco12571-bib-0098","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2011-04-348367","article-title":"Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma","volume":"118","author":"Griffiths","year":"2011","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0470","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0470","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/11\/1337\/41914787\/oncolo_23_11_1337.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/11\/1337\/41914787\/oncolo_23_11_1337.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T12:33:52Z","timestamp":1720355632000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/11\/1337\/6439739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,12]]},"references-count":98,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,6,12]]},"published-print":{"date-parts":[[2018,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0470","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,11,1]]},"published":{"date-parts":[[2018,6,12]]}}}